Andrew Hall
Chief Executive Officer bij IMV INC.
Vermogen: 12 $ op 31-12-2023
Profiel
Andrew Hall is currently the Chief Executive Officer & Director at IMV, Inc. He previously worked as an Executive Director of Business Development at Celgene Corp.
and as an Executive Director of Global Women's Health at Merck & Co., Inc. Mr. Hall completed his undergraduate degree at the University of Melbourne and his graduate degree at RMIT University.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
IMV INC.
0.05% | 20-03-2023 | 6 100 ( 0.05% ) | 12 $ | 31-12-2023 |
Actieve functies van Andrew Hall
Bedrijven | Functie | Begin |
---|---|---|
IMV INC. | Chief Executive Officer | 04-08-2021 |
Eerdere bekende functies van Andrew Hall
Bedrijven | Functie | Einde |
---|---|---|
MERCK & CO., INC. | Corporate Officer/Principal | - |
CELGENE | Corporate Officer/Principal | - |
Opleiding van Andrew Hall
University of Melbourne | Undergraduate Degree |
RMIT University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
IMV INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |